The initiation of drug therapy results in a reduction in the human immunodeficiency virus type 1 (HIV-1) population, which represents a potential genetic bottleneck. The effect of this druginduced genetic bottleneck on the population dynamics of the envelope (Env) regions has been addressed in several in vivo studies. However, it is difficult to investigate the effect on the env gene of the genetic bottleneck induced not only by entry inhibitors but also by non-entry inhibitors, particularly in vivo. Therefore, this study used an in vitro selection system using unique bulk primary isolates established in the laboratory to observe the effects of the antiretroviral druginduced bottleneck on the integrase and env genes. Env diversity was decreased significantly in one primary isolate [KP-1, harbouring both CXCR4 (X4)-and CCR5 (R5)-tropic variants] when passaged in the presence or absence of raltegravir (RAL) during in vitro selection. Furthermore, the RAL-selected KP-1 variant had a completely different Env sequence from that in the passage control (particularly evident in the gp120, V1/V2 and V4-loop regions), and a different number of potential N-glycosylation sites. A similar pattern was also observed in other primary isolates when using different classes of drugs. This is the first study to explore the influence of anti-HIV drugs on bottlenecks in bulk primary HIV isolates with highly diverse Env sequences using in vitro selection.
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) shows a high degree of genetic diversity owing to its high rates of replication and recombination and the high mutation rate of the HIV-1 reverse transcriptase (Nájera et al., 2002) . Even in a single infected individual, the virus can best be described as a population of distinct, but closely related, genetic variants or 'quasi-species' (Eigen, 1993; Nijhuis et al., 1998) . The quasi-species behaviour of viruses is recognized as a key element in our understanding and modelling of viral evolution and disease control (Vignuzzi et al., 2006) . Combination antiretroviral (ARV) therapy results in a contraction of the viral population, which represents a potential genetic bottleneck (Charpentier et al., 2006; Delwart et al., 1998; Ibáñez et al., 2000; Kitrinos et al., 2005; Nijhuis et al., 1998; Nora et al., 2007; Sheehy et al., 1996; Zhang et al., 1994) . Whilst this bottleneck has a direct effect on the region that is being targeted by the drugs (e.g. protease or reverse transcriptase), it also affects other regions of the viral genome. Indeed, the effect of the druginduced genetic bottleneck on the population dynamics of the envelope (Env) regions has been addressed in several in vivo studies (Charpentier et al., 2006; Delwart et al., 1998; Ibáñez et al., 2000; Kitrinos et al., 2005; Nijhuis et al., 1998; Nora et al., 2007; Sheehy et al., 1996; Zhang et al., 1994) .
Virus bottleneck evolution of the HIV-1 env gene might be important when choosing the optimal drugs to treat a particular patient. Indeed, a CCR5 antagonist (maraviroc, MVC) and a fusion inhibitor (enfuvirtide, T-20) have now been approved for use as HIV-1 entry inhibitors. Analysing the dynamics of drug-induced genetic bottlenecks and studying drug-resistant mutation profiles in response to HIV-1-specific ARV drugs are both important if we are to understand fully HIV-1 drug resistance and pathogenesis.
The aim of the present study was to understand better the effect of in vivo drug-induced genetic bottlenecks. In vitro selection of different primary HIV-1 isolates was performed using the recently approved HIV integrase inhibitor raltegravir (RAL) (Steigbigel et al., 2008) . Two R5-, one X4-, one dual-and one mixed R5/X4-tropic isolates were passaged through a RAL-induced genetic bottleneck. We also performed in vitro selection of the R5/ X4 isolate using lamivudine (3TC), saquinavir (SQV) and MVC, and compared the results with those from the RALselected isolate.
RESULTS

Genotypic profiles of the HIV-1 primary isolates
Four genetically heterogeneous HIV-1 primary isolates (KP-1-4) from Japanese drug-naïve patients were used to assess the extent to which RAL affected the selection of bulk primary viruses in vitro. A laboratory isolate, strain 89.6, was also used in the study (rather than a molecular clone) to allow escape mutants to be selected from each quasi-species pool and to be generated de novo. First, the sequences of the integrase (IN) regions of the four primary isolates were determined. Table 1 shows the detailed evaluation of the R5/ X4 mixture subtype B (KP-1), R5-CRF08_BC (KP-2), R5 subtype B (KP-3) and X4-CRF01_AE (KP-4) primary isolates, and the dual-tropic subtype B laboratory virus (89.6). Although some naturally occurring polymorphisms were observed within the IN regions of these isolates compared with the subtype B consensus sequence available from the Los Alamos National Laboratory HIV sequence database, we did not identify any primary resistant mutations to RAL. Three baseline viruses (KP-1, KP-4 and 89.6) were sensitive to RAL, with IC 50 values ranging from 1.2 to 4 nM, which are comparable with those reported previously (Kobayashi et al., 2008) . However, KP-2 and KP-3 showed minor resistance to RAL, with IC 50 values of 16 and 32 nM, respectively. These two isolates contained amino acid mutations at positions 72, 125 and 201 within the IN region [previously reported as L-870,810 and S-1360 resistance mutations (Hombrouck et al., 2008; Rhee et al., 2008) , but not as RAL-resistance mutations]. KP-2 also contained a unique insertion at position 288 (NQDME) at the C-terminal end of the IN region.
In vitro selection of variants of the primary isolates and 89.6 using RAL To induce RAL-selected HIV-1 variants in vitro, PM1/ CCR5 cells, a T-cell line expressing high levels of CCR5, were exposed to the four primary isolates and strain 89.6. The viruses were then serially passaged in the presence of RAL. As a control, each isolate was passaged under the same conditions, but without RAL, to allow monitoring of spontaneous changes occurring in the viruses during prolonged PM1/CCR5 cell passage (the passage control). The selected viruses were initially propagated at a RAL concentration equal to each IC 50 value. The RAL concentrations were then increased from 20 to 85 nM during the course of the selection procedure (Table 1) .
Only small shifts in the IC 50 to RAL were observed in four of the five isolates (KP-1, KP-2, KP-4 and 89.6), with fold changes in IC 50 values of 3.4, 6.5, 16 and 9.2, respectively. KP-3 did not show resistance to RAL. IC 50 values in all the passage controls were comparable with those of the baseline viruses (Table 1) .
IN region sequences in RAL-selected variants
The full-length IN genes were amplified and cloned to determine the genetic basis of selection in the presence or absence of RAL. Ten to 12 clones from each sample were sequenced.
Substitutions within IN were observed at passages 30 (G189R) and 29 (T210I) in two RAL-selected isolates (KP-2 and KP-4, respectively). Neither of these has been reported as IN inhibitor-resistant mutations. No substitutions in the IN regions of KP-3 and 89.6 were found. However, A125T and V180I substitutions were observed in the KP-3 and 89.6 control variants at the last passage. No previously reported mutations were identified in the IN region of KP-1 (an R5/ X4 mixture isolate) after 17 passages. However, four amino acids (K7/K111/H216/D278) were selected by RAL from the baseline quasi-species, whereas different amino acids (R7/ R111/Q216/N278) were selected in the control-passage variants (Table 1) .
Taken together, these findings showed that RAL-induced selection pressure causes adaptation within the IN regions of bulk primary viruses during in vitro passage in the target cells, and confirmed that this system can be used to analyse drug-selected variants in vitro.
Comparison of env gene sequences in RALselected and passage-control isolates A highly diverse gp120 region was observed in the baseline R5/X4 mixture isolate, KP-1; however, the viral diversity of variants passaged in the presence or absence of RAL decreased significantly during in vitro selection (overall mean distance after RAL selection of 0.056 at baseline to 0.007 after passage 17; mean overall distance in the passage control of 0.01 after 20 passages, Table 2 ). Moreover, the RAL-selected and control variants utilized CCR5 to enter the target cell; neither variant used CXCR4 (Table 3) . Interestingly, the low-diversity RAL-selected variant contained a completely different Env sequence from that of the passage-control variant (Fig. 1a) The results showed that, after only two passages, the gp120, V1/V2 and V4-loop regions within RAL-selected variants were longer than those in the control variants, and the number of putative N-linked glycosylation sites (PNGs) was significantly higher than that in the control-passage viruses (Table 2 ). This phenomenon was seen consistently in two independent experiments.
We also analysed the gp120 sequences in the other four isolates. Although the number of positional differences between the RAL-selected and passage-control variants for these four isolates was lower than that in KP-1 (between three and nine, compared with .40), there was a similar pattern of separation between the Env sequences ( Fig. 1) . In three of the four isolates (KP-2, KP-3 and KP-4), positional differences were observed in SP, C1 and all the variable regions of gp120 . In strain 89.6, differences were observed in the C2, C3 and V4 regions (Fig. 1e ).
These results suggested that RAL treatment of target cells causes a decrease in viral diversification within quasispecies Env regions via a route different from that in untreated target cells.
In vitro induction of RAL-selected V3-loop library virus variants
To investigate further the effects of RAL on viral Env sequences, we used the V3-loop library virus (JR-FLV3Lib) developed by Yusa et al. (2005) , which carries a set of random combinations from zero to ten substitutions (27 648 possibilities) in the V3 loop (residues 305, 306, 307, 308, 309, 317, 319, 322, 323 and 326; V3 loop from Cys 296 to Cys
331
). The variants contained in the library were polymorphic mutations derived from 31 R5 clinical isolates (Yusa et al., 2005) . PM1/CCR5 cells were exposed to the JR-FL-V3Lib and serially passaged in the presence of RAL. After two passages, the V3 sequence within the RALselected variant was completely different from that in the passage control (Fig. 1f) . This suggested that, under pressure from RAL, the infectious clone harbouring different V3 region sequence from the passage control had adapted to the target cells, despite containing the same IN sequences.
Phylogenetic analysis of the Env regions after passage with or without RAL
To confirm the temporal and spatial differences observed in each of the RAL-selected and passage-control viruses, phylogenetic analyses were conducted using complete SP-V5 sequences. The neighbour-joining phylogenetic tree showed a clear and distinct branching between RALselected and passage-control KP-1 viruses (Fig. 2a) . We also identified a similar pattern in all the other isolates tested (Fig. 2b-e) . 
In vitro selection of KP-1 variants by 3TC, SQV and MVC
To determine whether other HIV drugs also changed the route of adaptation to the target cells, we attempted to select KP-1 variants using a reverse transcriptase inhibitor (3TC), a protease inhibitor (SQV) and a CCR5 inhibitor (MVC). As shown in Fig. 2(f) , the pattern of clustering at distinct positions between the selected isolates and the passage-control variants was similar to that observed for the RAL-selected variants. The selected variants showed decreased diversity in the gp120 sequences; however, the length of the gp120, V1/V2 and V4 sequences increased (apart from in the MVC-selected variants). In addition, the number of PNGs within gp120 was higher than that in the control (Table 3) . We also compared the V3 sequences between the passage-control and each of the drug-selected variants. The V3 sequences in all the SQV-selected variants and 83.3 % of those in the 3TC-selected variants, were comparable with those in the RAL-selected variants. This was not the case for the passage controls. Comparison of variants passaged with RAL and 3TC showed that the length of the V1/V2 and V4 regions and the number of PNGs was similar; however, these parameters were different in the SQV-selected variants (Table 3 ). This indicated that the time at which a drug acts (e.g. during the early or late phase of the HIV life cycle) influences the selection of Env sequences. During selection with MVC, CXCR4-tropic variants were selected from the baseline mixture after seven passages.
Taken together, these results suggested that, in treated cells, different classes of anti-HIV drugs may suppress the variability of quasi-species during in vitro selection via a route different from that in untreated cells.
DISCUSSION
This study evaluated the impact of anti-HIV drugs on the Env bottleneck in bulk HIV-1 primary isolates during selection in vitro. RAL-, 3TC-and SQV-selected variants of the unique viral isolate, KP-1, harbouring both X4 and R5 variants and with a very high level of baseline viral diversity, were used to study the final destination (genetic bottleneck) of a large variety of Env sequences. Interestingly, the phylogenetic clustering of RAL-selected KP-1 variants was completely different from that of non-drug-treated controls (Fig. 2) . Our results also confirmed differences in the length of the gp120, V1/V2 and V4-loop regions and in the number of PNGs (Tables 2 and 3 Fig. 1 ) sequentially accumulated mutations in the same proviral genome (Fig.  S1 , available in JGV Online). However, we did not find a clone including both the RAL-selected Env at passage 17 and RAL-selected IN at passage 17 in the baseline or each passaged virus, except for in the last passage. We also examined the gp120 and IN sequences of the 3TC-and SQV-selected KP-1 variants. Compared with the RALselected region, the variable regions of gp120 in these selected variants were very similar to each other, except for the V1/V2 region (Fig. S2) . However, the passage-control variant was very different from the drug-selected variants (Fig. 1a) . Furthermore, the IN sequences were different in each passaged virus: K111/D278/H216/K7 in RAL-selected, R111/D278/Q216/R7 in 3TC-selected, K111/D278/H216/R7 in SQV-selected and R111/N278/Q216/R7 in virus without drug treatment (underlined residues indicate amino acids different from those in viruses without drug treatment). To explain these results, we believe that, under pressure from anti-HIV drugs (non-entry ARVs), the virus might show a primitive reaction to select for the Env sequence and recombine from quasi-species to gain advantage for entry and/or enhance replication in target cells. Meanwhile, IN was selected from quasi-species by a direct and/or indirect effect of RAL-induced pressure. The combination of both selective pressures may affect the selection for Env and IN during adaptation in drug-treated conditions (Figs 1a and  S2 ). These results suggest that non-entry inhibitors, such as RAL, 3TC and SQV, might also affect cell adaptation to PM1/CCR5 cells.
Many in vivo studies have reported the effects of the anti-HIV drug-induced bottleneck on the env gene (Charpentier et al., 2006; Delwart et al., 1998; Ibáñez et al., 2000; Kitrinos et al., 2005; Nijhuis et al., 1998; Nora et al., 2007; Sheehy et al., 1996; Zhang et al., 1994) . However, these studies had several limitations. Because viruses were placed under in vivo selective pressure using at least two anti-HIV drugs and by the host immune response, it is difficult to separate the different effects and to draw clear conclusions, particularly in vivo. Delwart et al. (1998) and Kitrinos et al. (2005) avoided some of these limitations by employing a heteroduplex tracking assay, although in vivo peculiarities still remained. Therefore, we used an in vitro selection system using unique bulk primary isolates established in our laboratory Yoshimura et al., 2006 Yoshimura et al., , 2010b to observe the effects of the anti-retroviral druginduced bottleneck on the IN and env genes.
This selection provides a sensitive approach for analysing virus population dynamics. The effectiveness of ARV drugs can be examined during the in vitro passage of a single variant or mixture of variants without being affected by many of the factors encountered in vivo. In addition, differences in the Env sequences between the baseline and selected variants can be compared after any number of passages. The results of the present study provide important information that will enhance our understanding of the drug-induced genetic bottleneck. This phenomenon can be examined in vitro using bulk primary isolates treated with or without drugs.
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PC 2 Phylogenetic trees were constructed using gp120 SP-V5 sequences from RAL-selected and passage-control variants of KP-1 (a), KP-2 (b), KP-3 (c), and strain 89.6 (e). An '¾' represents baseline (BL) variants, and closed and open symbols represent RAL-selected (RAL) and passage-control (PC) variants, respectively. In (a), the results of the second experiment are indicated as RAL2 and PC2, respectively. (f) A phylogenetic tree was constructed using gp120 SP-V5 sequences from RAL-, 3TC-, SQV-, MVC-selected and control-passaged variants of KP-1. #, Control variants after eight passages; $, RAL-selected variants after eight passages; m, 3TC-selected variants after six passages; X, SQV-selected variants after 11 passages; &, MVC-selected variants after seven passages. The trees were constructed using the neighbour-joining algorithm embedded within the MEGA software.
first CCR5 inhibitor (Gulick et al., 2008) . One important advantage associated with this drug is the absence of cross-resistance with previously available ARV compounds (Gulick et al., 2008; Steigbigel et al., 2008) . However, as is usual with anti-HIV drugs, resistant variants with mutations in the Env, gp120 and gp41 sequences are induced both in vivo and in vitro (Anastassopoulou et al., 2009; Berro et al., 2009; Tilton et al., 2010; Yoshimura et al., 2009 Yoshimura et al., , 2010a . As shown in the present study, distinct Env sequences from each quasispecies might be selected by the different anti-HIV drugs (e.g. length of the V1/2 and/or V4 regions, V3 region depletion and the number of PNGs). Moreover, many of the novel anti-retroviral drugs in pre-clinical trials are viral entry inhibitors (e.g. PRO140, ibalizumab, BMS-663068 and PF-232798; Jacobson et al., 2010; McNicholas et al., 2010; Nettles et al., 2011; Stupple et al., 2011; Toma et al., 2011) . Therefore, it is necessary to examine whether such entry inhibitors are effective when used alongside conventional drugs.
In conclusion, we studied the genetic bottleneck in bulk primary HIV-1 isolates from untreated patients and drugs targeting the Env (and other) regions. The results showed, for the first time, the presence of drug-selected Env sequences in these isolates. Although our observations were based on a limited number of HIV-1 isolates and need to be confirmed by independent studies, we believe that they provide a new paradigm for HIV-1 evolution in the new combination ARV therapy era.
METHODS
Patients and isolates. Primary HIV-1 isolates were isolated from four drug-naïve patients in our laboratory (KP-1-4) and passaged in phytohaemagglutinin-activated PBMCs. Infected PBMCs were then co-cultured for 5 days with PM1/CCR5 cells (a kind gift from Dr Y. Maeda et al., 2008; Yusa et al., 2005) and the culture supernatants were stored at 2150 uC Yoshimura et al., 2006 Yoshimura et al., , 2010b .
After isolation of the primary viruses, we checked the sensitivity of each primary isolate to MVC. The KP-1 isolate was relatively MVCresistant compared with KP-2 and KP-3 (54 vs 5.9 and 8.7 nM, respectively). KP-1 became MVC sensitive after eight passages in PM1/CCR5 cells [IC 50 , 3.4 nM; Geno2pheno value (see below), 41.2 %], whilst under the pressure of MVC, KP-1 became highly resistant to MVC after eight passages (IC 50 , .1000 nM; Geno2pheno value, 1.7 %). These results indicated that the bulk KP-1 isolate used in this study harboured primarily R5 viruses with X4-or dual-tropic viruses as a minor population.
Cells, culture conditions and reagents. PM1/CCR5 cells were maintained in RPMI 1640 (Sigma) supplemented with 10 % heatinactivated FCS (HyClone Laboratories), 50 U penicillin ml 21 , 50 mg streptomycin ml 21 and 0.1 mg G418 (Nacalai Tesque) ml 21 . MVC, RAL and SQV were kindly provided by Pfizer, Merck & Co. and Roche Products, respectively. 3TC was purchased from Wako Pure Chemical Industries. Effect of ARV therapy on the HIV-1 genetic bottleneck
